Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Ammirati, Enrico ^a,b   Moroni, Francesco ^a   Norata, Giuseppe Danilo ^c,d,e   Magnoni, Marco ^a   Camici, Paolo G ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d Bassini Hospital   (Italy)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LIPID; C REACTIVE PROTEIN; INTERLEUKIN 6;

ARTERIAL WALL THICKNESS; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; INFLAMMATION; LEUKOCYTE; NEOVASCULARIZATION (PATHOLOGY); NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; ATHEROSCLEROTIC PLAQUE; BLOOD; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CAROTID ARTERY DISEASE; IMMUNE SYSTEM; METABOLISM; RISK FACTOR;

BIOMARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; DISEASE PROGRESSION; HUMANS; IMMUNE SYSTEM; INFLAMMATION; INTERLEUKIN-6; LIPIDS; NEOVASCULARIZATION, PATHOLOGIC; PLAQUE, ATHEROSCLEROTIC; RISK FACTORS;

EID: 84928786596     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/718329     Document Type: Review

References (121)

1. M. de Weerd, J. P. Greving, B. Hedblad et al., "Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant datameta-analysis," Stroke, vol. 41, no. 6, pp. 1294-1297, 2010.
2. A.G. den Hartog, S. Achterberg, F. L. Moll et al., "Asymptomatic carotid artery stenosis and the risk of ischemic stroke according to subtype in patients with clinical manifest arterial disease," Stroke, vol. 44, no. 4, pp. 1002-1007, 2013.
3. J. W. Norris, C. Z. Zhu, N.M. Bornstein, and B. R. Chambers, "Vascular risks of asymptomatic carotid stenosis," Stroke, vol. 22, no. 12, pp. 1485-1490, 1991.
4. D. Inzitari, M. Eliasziw, P. Gates et al., "The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators," The New England Journal of Medicine, vol. 342, no. 23, pp. 1693-1700, 2000.
5. G. W. Petty, R. D. Brown Jr., J. P. Whisnant, J. D. Sicks, W. M. O'Fallon, and D. O. Wiebers, "Ischemic stroke subtypes: a population-based study of incidence and risk factors," Stroke, vol. 30, no. 12, pp. 2513-2516, 1999.
6. P. M. Rothwell, R. Gibson, and C. P. Warlow, "Interrelation between plaque surface morphology and degree of stenosis on carotid angiograms and the risk of ischemic stroke in patients with symptomatic carotid stenosis," Stroke, vol. 31, no. 3, pp.615-621, 2000.
7. M. Tendera, V. Aboyans, M. Bartelink et al., "ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC)," European Heart Journal, vol. 32, no. 22, pp. 2851-2906, 2011.
8. O. Benavente, D. Moher, and B. Pham, "Carotid endarterectomy for asymptomatic carotid stenosis: a meta-analysis," British Medical Journal, vol. 317, no. 7171, pp. 1477-1480, 1998.
9. G. Raman, D. Moorthy, N. Hadar et al., "Management strategies for asymptomatic carotid stenosis: a systematic review and meta-analysis," Annals of Internal Medicine, vol. 158, no. 9, pp. 676-685, 2013.
10. J. D. Spence, "Asymptomatic carotid stenosis," Circulation, vol. 127, no. 6, pp. 739-742, 2013.
11. E. Ammirati, M. Magnoni, and P. G. Camici, "Need for new non-invasive imaging strategies to identify high-risk asymptomatic patients with carotid stenosis," International Journal of Cardiology, vol. 168, no. 4, pp. 4342-4343, 2013.
12. S. C. Johnston, E. S. O'Meara, T. A. Manolio et al., "Cognitive impairment and decline are associated with carotid artery disease in patients without clinically evident cerebrovascular disease," Annals of Internal Medicine, vol. 140, no. 4, pp. 237-247, 2004.
13. L. Buratti, C. Balucani, G. Viticchi et al., "Cognitive deterioration in bilateral asymptomatic severe carotid stenosis," Stroke, vol. 45, no. 7, pp. 2072-2077, 2014.
14. S. Balestrini, C. Perozzi, C. Altamura et al., "Severe carotid stenosis and impaired cerebral hemodynamics can influence cognitive deterioration," Neurology, vol. 80, no. 23, pp. 2145-2150, 2013.
15. G. Jayasooriya, A. Thapar, J. Shalhoub, and A. H. Davies, "Silent cerebral events in asymptomatic carotid stenosis," Journal of Vascular Surgery, vol. 54, no. 1, pp. 227-236, 2011.
16. H. H. Oei, I. M. van der Meer, A. Hofman et al., "Lipoproteinassociated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study," Circulation, vol. 111, no. 5, pp. 570-575, 2005.
17. V. Nambi, R. C. Hoogeveen, L. Chambless et al., "Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the atherosclerosis risk in communities (ARIC) study," Stroke, vol. 40, no. 2, pp. 376-381, 2009.
18. P.M. Ridker, M. Cushman, M. J. Stampfer et al., "Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men," The New England Journal of Medicine, vol. 336, no. 14, pp. 973-979, 1997.
19. P. M. Ridker, J. E. Buring, J. Shih, M. Matias, and C. H. Hennekens, "Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women," Circulation, vol. 98, no. 8, pp. 731-733, 1998.
20. N. S. Rost, P. A. Wolf, C. S. Kase et al., "Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham Study," Stroke, vol. 32, no. 11, pp. 2575-2579, 2001.
21. M. W. Lorenz, J. F. Polak, M. Kavousi et al., "Carotid intimamedia thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data," The Lancet, vol. 379, no. 9831, pp. 2053-2062, 2012.
22. P. Willeit, S. G. Thompson, S. Agewall et al., "Inflammatory markers and extent and progression of early atherosclerosis: meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMTCollaboration," European Journal of Preventive Cardiology, 2014.
23. L. Hermus, J. D. Lefrandt, R. A. Tio, J.-C. Breek, and C. J. Zeebregts, "Carotid plaque formation and serum biomarkers," Atherosclerosis, vol. 213, no. 1, pp. 21-29, 2010.
24. P. Puz, A. Lasek-Bal, D. Ziaja, Z. Kazibutowska, and K. Ziaja, "Inflammatory markers in patients with internal carotid artery stenosis," Archives of Medical Science, vol. 9, no. 2, pp. 254-260, 2013.
25. E. Debing, E. Peeters, C. Demanet, M. de Waele, and P. van den Brande, "Markers of inflammation in patients with symptomatic and asymptomatic carotid artery stenosis: a casecontrol study," Vascular and Endovascular Surgery, vol. 42, no. 2, pp. 122-127, 2008.
26. D. S. Halvorsen, S. H. Johnsen, E. B. Mathiesen, and I. Njølstad, "The association between inflammatory markers and carotid atherosclerosis is sex dependent: the Tromsø study," Cerebrovascular Diseases, vol. 27, no. 4, pp. 392-397, 2009.
27. C.M. L. Chapman, J. P. Beilby, B. M. McQuillan, P. L. Thompson, and J. Hung, "Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis," Stroke, vol. 35, no. 7, pp. 1619-1624, 2004.
28. G. D. Norata, C. Garlanda, and A. L. Catapano, "The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases," Trends in Cardiovascular Medicine, vol. 20, no. 2, pp. 35-40, 2010.
29. F. Bonacina, A. Baragetti, A. L. Catapano, and G. D. Norata, "Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases," Mediators of Inflammation, vol. 2013, Article ID 725102, 10 pages, 2013.
30. G. D. Norata, P. Marchesi, A. Pirillo et al., "Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 5, pp. 925-931, 2008.
31. G. D. Norata, P. Marchesi, V. K. Pulakazhi Venu et al., "Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis," Circulation, vol. 120, no. 8, pp. 699-708, 2009.
32. M. Knoflach, S. Kiechl, A. Mantovani et al., "Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY Studies," PLoS ONE, vol. 7, no. 2, Article ID e31474, 2012.
33. A. Baragetti, M. Knoflach, I. Cuccovillo et al., "Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general population," Nutrition, Metabolism and Cardiovascular Diseases, vol. 24, no. 5, pp. 518-523, 2014.
34. A. Abbas, P. Aukrust, T. B. Dahl et al., "High levels of S100A12 are associated with recent plaque symptomatology in patients with carotid atherosclerosis," Stroke, vol. 43, no. 5, pp. 1347-1353, 2012.
35. J. Andersson, J. Sundström, L. Kurland et al., "The carotid artery plaque size and echogenicity are related to different cardiovascular risk factors in the elderly: the prospective investigation of the vasculature in uppsala seniors (PIVUS) study," Lipids, vol. 44, no. 5, pp. 397-403, 2009.
36. P. G. Camici, O. E. Rimoldi, O. Gaemperli, and P. Libby, "Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque," European Heart Journal, vol. 33, no. 11, pp. 1309-1317, 2012.
37. A. V. Finn, M. Nakano, J. Narula, F. D. Kolodgie, and R. Virmani, "Concept of vulnerable/unstable plaque," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 7, pp. 1282-1292, 2010.
38. A. Shindo, H. Tanemura, K. Yata et al., "Inflammatory biomarkers in atherosclerosis: pentraxin 3 can become a novel marker of plaque vulnerability," PLoS ONE, vol. 9, no. 6, Article ID e100045, 2014.
39. S. Willems, P. H. A. Quax, G. J. de Borst et al., "Soluble ST2 levels are not associated with secondary cardiovascular events and vulnerable plaque phenotype in patients with carotid artery stenosis," Atherosclerosis, vol. 231, no. 1, pp. 48-53, 2013.
40. K. Sugioka, T. Naruko, T. Hozumi et al., "Elevated levels of neopterin are associated with carotid plaques with complex morphology in patients with stable angina pectoris," Atherosclerosis, vol. 208, no. 2, pp. 524-530, 2010.
41. J. Pelisek, M. Rudelius, P. Zepper et al., "Multiple biological predictors for vulnerable carotid lesions," Cerebrovascular Diseases, vol. 28, no. 6, pp. 601-610, 2009.
42. Z. S. Galis and J. J. Khatri, "Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly," Circulation Research, vol. 90, no. 3, pp. 251-262, 2002.
43. J. L. Johnson, N. P. Jenkins, W. C. Huang et al., "Relationship of MMP-14 and TIMP-3 expression with macrophage activation and human atherosclerotic plaque vulnerability," Mediators of Inflammation, vol. 2014, Article ID 276457, 17 pages, 2014.
44. C. Cheng, D. Tempel, R. van Haperen et al., "Activation of MMP8 and MMP13 by angiotensin II correlates to severe intraplaque hemorrhages and collagen breakdown in atherosclerotic lesions with a vulnerable phenotype," Atherosclerosis, vol. 204, no. 1, pp. 26-33, 2009.
45. M. Koutouzis, L. S. Rallidis, G. Peros et al., "Serum interleukin- 6 is elevated in symptomatic carotid bifurcation disease," Acta Neurologica Scandinavica, vol. 119, no. 2, pp. 119-125, 2009.
46. B. A. Garcia, C. Ruiz, P. Chacon, J. A. Sabin, and M. Matas, "High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque," Journal of Vascular Surgery, vol. 38, no. 5, pp. 1018-1024, 2003.
47. A. Handberg, M. Skjelland, A. E. Michelsen et al., "Soluble CD36 in plasma is increased in patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability," Stroke, vol. 39, no. 11, pp. 3092-3095, 2008.
48. D. C. Rijken and H. R. Lijnen, "New insights into themolecular mechanisms of the fibrinolytic system," Journal of Thrombosis and Haemostasis, vol. 7, no. 1, pp. 4-13, 2009.
49. A. Edsfeldt, M. Nitulescu, H. Grufman et al., "Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque," Stroke, vol. 43, no. 12, pp. 3305-3312, 2012.
50. F. J. Olson, T. Thurison, M. Ryndel, G. Høyer-Hansen, and B. Fagerberg, "Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability," Clinical Biochemistry, vol. 43, no. 1-2, pp. 124-130, 2010.
51. G. Basta, M. Castagnini, S. del Turco et al., "High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis," European Journal of Clinical Investigation, vol. 39, no. 12, pp. 1065-1072, 2009.
52. A. Abbas, P. Aukrust, D. Russell et al., "Matrix metalloproteinase 7 is associated with symptomatic lesions and adverse events in patients with carotid atherosclerosis," PLoS ONE, vol. 9, no. 1, Article ID e84935, 2014.
53. P. Libby, "Inflammation in atherosclerosis," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 9, pp. 2045-2051, 2012.
54. E. Ammirati, F. Moroni, P. Pedrotti et al., "Non-invasive imaging of vascular inflammation," Frontiers in Immunology, vol. 5, article 399, 2014.
55. R. Duivenvoorden, V. Mani, M. Woodward et al., "Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study," JACC: Cardiovascular Imaging, vol. 6, no. 10, pp. 1087-1094, 2013.
56. V. Mani, M. Woodward, D. Samber et al., "Predictors of change in carotid atherosclerotic plaque inflammation and burden as measured by 18-FDG-PET and MRI, respectively, in the dal-PLAQUE study," The International Journal of Cardiovascular Imaging, vol. 30, no. 3, pp. 571-582, 2014.
57. J. H. F. Rudd, K. S. Myers, S. Bansilal et al., "Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positronemission tomography/computed tomography imaging study," Circulation: Cardiovascular Imaging, vol. 2, no. 2, pp. 107-115, 2009.
58. H. Grufman, I. Gonçalves, A. Edsfeldt et al., "Plasma levels of high-sensitive C-reactive protein do not correlate with inflammatory activity in carotid atherosclerotic plaques," Journal of Internal Medicine, vol. 275, no. 2, pp. 127-133, 2014.
59. C. Bonnans, J. Chou, and Z. Werb, "Remodelling the extracellular matrix in development and disease," Nature Reviews Molecular Cell Biology, vol. 15, no. 12, pp. 786-801, 2014.
60. A. Müller, S.D. Krämer, R. Meletta et al., "Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability," Nuclear Medicine and Biology, vol. 41, no. 7, pp. 562-569, 2014.
61. G. D. Norata, C. M. Ballantyne, and A. L. Catapano, "New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs," European Heart Journal, vol. 34, no. 24, pp. 1783-1789, 2013.
62. M. A. Austin, J. L. Breslow, C. H. Hennekens, J. E. Buring, W. C. Willett, and R.M. Krauss, "Low-density lipoprotein subclass patterns and risk of myocardial infarction," The Journal of the American Medical Association, vol. 260, no. 13, pp. 1917-1921, 1988.
63. M. J. Stampfer, R.M. Krauss, J. Ma et al., "A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction," Journal of the American Medical Association, vol. 276, no. 11, pp. 882-888, 1996.
64. A. C. St-Pierre, B. Cantin, G. R. Dagenais et al., "Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 3, pp. 553-559, 2005.
65. G. D. Norata, S. Raselli, L. Grigore et al., "Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells," Atherosclerosis, vol. 206, no. 2, pp. 556-562, 2009.
66. S. Koba, T. Hirano, T. Kondo et al., "Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease," American Heart Journal, vol. 144, no. 6, pp. 1026-1035, 2002.
67. G. D. Norata, L. Grigore, S. Raselli et al., "Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies," Atherosclerosis, vol. 193, no. 2, pp. 321-327, 2007.
68. A. L. Catapano, A. Pirillo, F. Bonacina, and G.D. Norata, "HDL in innate and adaptive immunity," Cardiovascular Research, vol. 103, no. 3, pp. 372-383, 2014.
69. G. D. Norata, A. Pirillo, E. Ammirati, and A. L. Catapano, "Emerging role of high density lipoproteins as a player in the immune system," Atherosclerosis, vol. 220, no. 1, pp. 11-21, 2012.
70. A. Pirillo, A. L. Catapano, and G. D. Norata, "HDL in infectious diseases and sepsis," in High Density Lipoproteins, vol. 224 of Handbook of Experimental Pharmacology, pp. 483-508, Springer, Berlin, Germany, 2015.
71. F. Montecucco, E. Favari, G. D. Norata, N. Ronda, J.-R. Nofer, and N. Vuilleumier, "Impact of systemic inflammation and autoimmune diseases on apoA-I and HDL plasma levels and functions," in High Density Lipoproteins, vol. 224 of Handbook of Experimental Pharmacology, pp. 455-482, 2015.
72. E. Ammirati, E. P. Bozzolo, R. Contri et al., "Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus," Nutrition, Metabolism and Cardiovascular Diseases, vol. 24, no. 7, pp. 751-759, 2014.
73. C. K. Glass and J. L. Witztum, "Atherosclerosis: the road ahead," Cell, vol. 104, no. 4, pp. 503-516, 2001.
74. L. Lind, T. Simon, L. Johansson et al., "Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality," European Heart Journal, vol. 33, no. 23, pp. 2946-2954, 2012.
75. J. M. Ordovas, "Identification of a functional polymorphism at the adipose fatty acid binding protein gene (FABP4) and demonstration of its association with cardiovascular disease: a path to follow," Nutrition Reviews, vol. 65, no. 3, pp. 130-134, 2007.
76. J. Saksi, P. Ijas, M. I. Mayranpaa et al., "Low-expression variant of fatty acid-binding protein 4 favors reduced manifestations of atherosclerotic disease and increased plaque stability," Circulation: Cardiovascular Genetics, vol. 7, no. 5, pp. 588-598, 2014.
77. S. Holm, T. Ueland, T. B. Dahl et al., "Fatty Acid binding protein 4 is associated with carotid atherosclerosis and outcome in patients with acute ischemic stroke," PLoS ONE, vol. 6, no. 12, Article ID e28785, 2011.
78. H.E. Agardh, L. Folkersen, J. Ekstrand et al., "Expressionof fatty acid-binding protein 4/aP2 is correlated with plaque instability in carotid atherosclerosis," Journal of Internal Medicine, vol. 269, no. 2, pp. 200-210, 2011.
79. G. D. Norata, I. Baragetti, S. Raselli et al., "Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status," Nutrition, Metabolism and Cardiovascular Diseases, vol. 20, no. 1, pp. 56-63, 2010.
80. G. D. Norata, S. Raselli, L. Grigore et al., "Leptin: adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery," Stroke, vol. 38, no. 10, pp. 2844-2846, 2007.
81. G. D. Norata, M. Ongari, K. Garlaschelli, S. Raselli, L. Grigore, and A. L. Catapano, "Plasma resistin levels correlate with determinants of the metabolic syndrome," European Journal of Endocrinology, vol. 156, no. 2, pp. 279-284, 2007.
82. F. Molica, S. Morel, B. R. Kwak, F. Rohner-Jeanrenaud, and S. Steffens, "Adipokines at the crossroad between obesity and cardiovascular disease," Thrombosis and Haemostasis, vol. 113, no. 3, pp. 553-566, 2015.
83. J. Van de Voorde, B. Pauwels, C. Boydens, and K. Decaluwé, "Adipocytokines in relation to cardiovascular disease," Metabolism: Clinical and Experimental, vol. 62, no. 11, pp. 1513-1521, 2013.
84. S. P. Perfetto, P. K. Chattopadhyay, and M. Roederer, "Seventeen-colour flow cytometry: unravelling the immune system," Nature Reviews Immunology, vol. 4, no. 8, pp. 648-655, 2004.
85. E. Ammirati, F. Moroni, M. Magnoni, and P. G. Camici, "The role of T and B cells in human atherosclerosis and atherothrombosis," Clinical & Experimental Immunology, vol. 179, no. 2, pp. 173-187, 2015.
86. A. S. Jaipersad, G. Y. H. Lip, S. Silverman, and E. Shantsila, "The role of monocytes in angiogenesis and atherosclerosis," Journal of the American College of Cardiology, vol. 63, no. 1, pp. 1-11, 2014.
87. F. J. Mayer, D. Gruenberger, M. Schillinger et al., "Prognostic value of neutrophils in patients with asymptomatic carotid artery disease," Atherosclerosis, vol. 231, no. 2, pp. 274-280, 2013.
88. N. Nasr, J. B. Ruidavets, J. F. Arnal, P. Sie, and V. Larrue, "Association of neutrophil count with microembolization in patients with symptomatic carotid artery stenosis," Atherosclerosis, vol. 207, no. 2, pp. 519-523, 2009.
89. K. Jurk, M. A. Ritter, C. Schriek et al., "Activated monocytes capture platelets for heterotypic association in patients with severe carotid artery stenosis," Thrombosis and Haemostasis, vol. 103, no. 6, pp. 1193-1202, 2010.
90. S. Massberg, K. Brand, S. Grüner et al., "A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation," The Journal of Experimental Medicine, vol. 196, no. 7, pp. 887-896, 2002.
91. M. A. Ritter, K. Jurk, C. Schriek et al., "Microembolic signals on transcranial doppler ultrasound are correlated with platelet activation markers, but not with platelet-leukocyte associates: a study in patients with acute stroke and in patients with asymptomatic carotid stenosis," Neurological Research, vol. 31, no. 1, pp. 11-16, 2009.
92. Z. Sternberg, H. Ghanim, K. M. Gillotti et al., "Flow cytometry and gene expression profiling of immune cells of the carotid plaque and peripheral blood," Atherosclerosis, vol. 229, no. 2, pp. 338-347, 2013.
93. J. L. Martin-Ventura, J. Madrigal-Matute, B. Munoz-Garcia et al., "Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells," Cardiovascular Research, vol. 83, no. 3, pp. 586-594, 2009.
94. P. T. Mantani, I. Ljungcrantz, L. Andersson et al., "Circulating CD40+ and CD86+ B cell subsets demonstrate opposing associations with risk of stroke," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 1, pp. 211-218, 2014.
95. S.W. Brouilette, J. S. Moore, A. D. McMahon et al., "Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested casecontrol study," The Lancet, vol. 369, no. 9556, pp. 107-114, 2007.
96. S. Brouilette, R. K. Singh, J. R. Thompson et al., "White cell telomere length and risk of premature myocardial infarction," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 5, pp. 842-846, 2003.
97. A. Baragetti, J. Palmen, K. Garlaschelli et al., "Telomere shortening over 6 years is associated with increased subclinical carotid vascular damage and worse cardiovascular prognosis in the general population," Journal of Internal Medicine, vol. 277, no. 4, pp. 478-487, 2015.
98. H. M. den Ruijter, S. A. Peters, T. J. Anderson et al., "Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis," The Journal of the American Medical Association, vol. 308, no. 8, pp. 796-803, 2012.
99. P.H. Davis, J.D. Dawson, W. A. Riley, and R.M. Lauer, "Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age the muscatine Study," Circulation, vol. 104, no. 23, pp. 2815-2819, 2001.
100. V. A. Korshunov and B. C. Berk, "Strain-dependent vascular remodeling: the 'Glagov phenomenon' is genetically determined," Circulation, vol. 110, no. 2, pp. 220-226, 2004.
101. E. M. Smolock, V. A. Korshunov, G. Glazko, X. Qiu, J. Gerloff, and B. C. Berk, "Ribosomal protein L17, RpL17, is an inhibitor of vascular smooth muscle growth and carotid intima formation," Circulation, vol. 126, no. 20, pp. 2418-2427, 2012.
102. C. Schulze Horn, R. Ilg, K. Sander et al., "High-sensitivity Creactive protein at different stages of atherosclerosis: results of the INVADE study," Journal of Neurology, vol. 256, no. 5, pp. 783-791, 2009.
103. J. Orbe, I. Montero, J. A. Rodríguez, O. Beloqui, C. Roncal, and J. A. Páramo, "Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis," Journal of Thrombosis and Haemostasis, vol. 5, no. 1, pp. 91-97, 2007.
104. N. C. Olson, M. F. Doyle, N. S. Jenny et al., "Decreasednaive and increased memory CD4+ T cells are associated with subclinical atherosclerosis: the multi-ethnic study of atherosclerosis," PLoS ONE, vol. 8, no. 8, Article ID e71498, 2013.
105. E. Ammirati, D. Cianflone, V. Vecchio et al., "Effectormemory T cells are associated with atherosclerosis in humans and animal models," Journal of the American Heart Association, vol. 1, no. 111, pp. 27-41, 2012.
106. K. S. Rogacev, C. Ulrich, L. Blömer et al., "Monocyte heterogeneity in obesity and subclinical atherosclerosis," European Heart Journal, vol. 31, no. 3, pp. 369-376, 2010.
107. H. M. Kwon, G. Sangiorgi, E. L. Ritman et al., "Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia," The Journal of Clinical Investigation, vol. 101, no. 8, pp. 1551-1556, 1998.
108. R. Virmani, F. D. Kolodgie, A. P. Burke et al., "Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 10, pp. 2054-2061, 2005.
109. S. Coli, M. Magnoni, G. Sangiorgi et al., "Contrast-enhanced ultrasound imaging of intraplaque neovascularization in carotid arteries: correlation with histology and plaque echogenicity," Journal of the American College of Cardiology, vol. 52, no. 3, pp. 223-230, 2008.
110. M. Magnoni, S. Coli, M. M. Marrocco-Trischitta et al., "Contrast-enhanced ultrasound imaging of periadventitial vasa vasorum in human carotid arteries," European Journal of Echocardiography, vol. 10, no. 2, pp. 260-264, 2009.
111. Y.-N. Qian, Y.-T. Luo, H.-X. Duan et al., "Adhesion molecule CD146 and its soluble form correlate well with carotid atherosclerosis and plaque instability," CNS Neuroscience & Therapeutics, vol. 20, no. 5, pp. 438-445, 2014.
112. J. Pelisek, G. Well, C. Reeps et al., "Neovascularization and angiogenic factors in advanced human carotid artery stenosis," Circulation Journal, vol. 76, no. 5, pp. 1274-1282, 2012.
113. A. S. Jaipersad, A. Shantsila, G. Y. Lip, and E. Shantsila, "Expression of monocyte subsets and angiogenic markers in relation to carotid plaque neovascularization in patients with pre-existing coronary artery disease and carotid stenosis," Annals of Medicine, vol. 46, no. 7, pp. 530-538, 2014.
114. F. Turnbull, "Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials," The Lancet, vol. 362, no. 9395, pp. 1527-1535, 2003.
115. C. M. Fichtenberg and S. A. Glantz, "Association of the California tobacco control program with declines in cigarette consumption and mortality from heart disease," The New England Journal of Medicine, vol. 343, no. 24, pp. 1772-1777, 2000.
116. B. Mihaylova, J. Emberson, L. Blackwell et al., "The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials," The Lancet, vol. 380, no. 9841, pp. 581-590, 2012.
117. P. M. Ridker, E. Danielson, F. A. Fonseca et al., "Reduction in Creactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial," The Lancet, vol. 373, no. 9670, pp. 1175-1182, 2009.
118. T.Y. Tang, S. P. S. Howarth, S. R. Miller et al., "The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease," Journal of the American College of Cardiology, vol. 53, no. 22, pp. 2039-2050, 2009.
119. R. Corti, V. Fuster, Z.A. Fayad et al., "Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, doubleblind trial with high-resolution magnetic resonance imaging," Journal of the American College of Cardiology, vol. 46, no. 1, pp. 106-112, 2005.
120. Z. A. Fayad, V. Mani, M. Woodward et al., "Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial," The Lancet, vol. 378, no. 9802, pp. 1547-1559, 2011.
121. M. Marnane, S. Prendeville, C. McDonnell et al., "Plaque inflammation and unstable morphology are associated with early stroke recurrence in symptomatic carotid stenosis," Stroke, vol. 45, no. 3, pp. 801-806, 2014.